Trial reportHuman psychopharmacology2026
Acute Caffeine Intake Does Not Modulate Active or Reactive Inhibition in Non-Clinical Young Adults, and ADHD Symptoms Do Not Moderate Its Effects.
Trial report in Human psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCaffeine is consumed for its presumed cognitive benefits, yet controlled studies have repeatedly failed to find effects on inhibitory control. Cross-sectional work suggests that people with elevated attention-deficit/hyperactivity disorder (ADHD) symptoms may benefit from chronic, moderate caffeine consumption, but whether acute intake improves cognition in proportion to symptom severity has not been tested experimentally.
aimsWe tested whether 250 mg of caffeine improves active inhibition (withholding a prepared response) and reactive inhibition (resolving response conflict), and whether ADHD symptom severity moderates these effects.
methodsIn a preregistered, randomised, double-blind, placebo-controlled crossover trial, a nonclinical sample of 36 young adults received 250 mg of caffeine or placebo in counterbalanced order, with testing 45 min after ingestion. Active inhibition was assessed with a Go/No-Go task (204 trials), reactive inhibition with an arrow flanker task (200 trials) and symptoms with the Adult ADHD Self-Report Scale. Mixed-effects models included treatment, symptom severity, their interaction and ten covariates; Bayes factors quantified evidence for the null.
resultsBoth tasks produced their benchmark effects (dz = 1.24 and 1.09) and all indices were reliable (split-half r = 0.73-0.98). Caffeine affected neither commission errors (BF01 = 4.98), response criterion (5.14), Go reaction time (2.83), reaction time variability (4.35), flanker reaction time (5.49) nor flanker accuracy (5.09). ADHD symptoms moderated no effect (15 preregistered tests; smallest p = 0.514), yet predicted performance itself (flanker accuracy r = -0.42), indicating that the null is not due to an insensitive measure.
conclusionsCaffeine produced no acute benefit for either form of inhibition, and ADHD symptoms did not moderate its effects. Bayes factors supported the absence rather than the nondetection of these effects, arguing against an acute improvement of inhibitory control that scales with ADHD symptom severity in nonclinical young adults. Whether this also holds for chronic consumption or for adults with diagnosed ADHD remains to be tested.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.